US EditionPrescient starts US recruitment in Phase 2a trial of PTX-100 for patients with rare blood cancer
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Prescient starts US recruitment in Phase 2a trial of PTX-100 for patients with rare blood cancer
Prescient initiates first US site for Phase 2a trial of PTX 100 in patients with rare blood cancer r/r CTCL. The newly activated site is renowned VCU Massey Comprehensive Cancer Centre in Virginia Site adds to three existing Australian sites, where four people have been enrolled Special Report: Prescient Therapeutics has reached a key milestone in its clinical development program, initiating its first US site for the Phase 2a trial of PTX-100 …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
